Journal profile · Medicine-Pulmonary and Respiratory Medicine
Pulmonary Therapy
ISSN 2364-1754 · eISSN 2364-1746 · Springer Nature · United Kingdom · 4 issues per year
Pulmonary Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.4 (journal website); fully open access; APC about USD 7,675; median 53 days to acceptance (96 articles, last 24 months); 56 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Pulmonary Therapy is published by Springer Nature and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research and Inhalation and Respiratory Drug Delivery, together about 45.9% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Aims and ScopePulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.Rapid PublicationThe journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies. Open Access All articles published by Pulmonary Therapy are open access. Personal ServiceThe journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that article
From the journal's Aims & Scope
Research area (LetPub): Medicine-Pulmonary and Respiratory Medicine
Editorial board by country: 3 in mainland China (about 3%); most named United States 24, United Kingdom 21, Italy 15, Canada 6, Australia 6 (102 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine18.8%
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine15.1%
- Inhalation and Respiratory Drug DeliveryMedicine12%
- Respiratory and Cough-Related ResearchMedicine8%
- Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedicine5.6%
- Respiratory Support and MechanismsMedicine5.2%
- Cystic Fibrosis Research AdvancesMedicine4.8%
- Delphi Technique in ResearchSocial Sciences4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 3.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 3Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.82LetPub ·
- SNIP 2026-06
- 1.13LetPub ·
- h-index
- 33OpenAlex ·
- i10-index
- 107OpenAlex ·
- 2-year mean citedness
- 2.89OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 50LetPub ·
- Downloads per year (publisher) 2025
- 347,000Publisher website ·
Articles by year OpenAlex count · 366 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 48 | 48 | 36 |
| 2025 | 56 | 56 | 170 |
| 2024 | 34 | 34 | 193 |
| 2023 | 36 | 36 | 456 |
| 2022 | 34 | 34 | 367 |
| 2021 | 35 | 35 | 541 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
53 daysMedian, submission to acceptance · P25–P75 40 days – 68 days
- Acceptance to online
- median 25 days (96 articles)
- Submission to online
- median 79 days
- Sample
- 96 articles with submission and acceptance dates (112 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Acceptance to publication
- 28 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 5,950 / USD 7,675 / GBP 5,120 | Yes | CC BY-NC | |
| OpenAlex | USD 7,400 / EUR 5,750 / GBP 4,900 | — | — | |
| LetPub | GBP 5,120 / USD 7,675 / EUR 5,950 | Yes | — | |
| Publisher website | GBP 5,120 / EUR 5,950 / USD 7,675 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access publishing
Open access publishing information available on a dedicated page. Model summary
To find out more about publishing your work Open Access in Pulmonary Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- United Kingdom
- Language
- English
- Frequency
- 4 issues per year
- ISSN
- 2364-1754
- Electronic ISSN
- 2364-1746
- Latest issue on the website
- Volume 12, Issue 3 (September 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Pulmonary Therapy
What CAS zone is Pulmonary Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Pulmonary Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Respiratory System. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Pulmonary Therapy?
The journal's website gives an impact factor of 3.4 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.9, h-index 33.
How long does peer review take at Pulmonary Therapy?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 53 days (interquartile range 40–68 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Pulmonary Therapy based?
Of the 102 board members whose country the journal's board page names, 3 (about 3%) are in mainland China; the countries named most often are United States (24), United Kingdom (21) and Italy (15). Counted from the institutions listed on the board page; for reference only.
Which databases index Pulmonary Therapy?
According to LetPub and DOAJ records, Pulmonary Therapy is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Embase; that list has not been checked against each database.
Is Pulmonary Therapy open access, and what is the APC?
Pulmonary Therapy is a fully open-access journal. APC about USD 7,675.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-30). Last updated: .